ArticleACS nano2022
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in ACS nano, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 135 citations in OpenAlex.
- Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.Nature communications · 2026Article
- Targeting a Myeloid-Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Integrin-mediated mechanotransduction in the tumor microenvironment: macrophage-centered signaling mechanisms and immune remodeling.Journal of translational medicine · 2026Review
- Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma.Cells · 2026Review
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Deciphering the glioblastoma microenvironmental landscape with multi-modal radiogenomics to guide prognosis and personalized therapy.Journal of translational medicine · 2026Article
- Pharmacological modulation of CXCL12/CXCR4/ACKR3 for brain disorders - an overview.Cell communication and signaling : CCS · 2026Review
- Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma.Cell death & disease · 2026Article
- The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma.Journal of cellular and molecular medicine · 2026Review
- Surface-Capped Protein Nanoparticles for Nonviral Gene Delivery.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- RAP-peptide functionalized biomimetic nanoformulation with pathological ROS/pH-responsive drug release for target immunotherapy in glioma.Journal of nanobiotechnology · 2026Article
- Targeted immunomodulation for chronic diseases through advanced delivery platforms.Expert opinion on drug delivery · 2026Review
- CXC Chemokine-Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The interrelationship between prostate cancer and osteoporosis: new perspectives on shared molecular pathways and treatment strategies.International journal of surgery (London, England) · 2026Article
- G-CSF promotes H3K27ac-modified KLF5 to activate CXCR4 expression and drive colon cancer growth and metastasis.European journal of medical research · 2026Article
- Magnetic Nanoparticles as a Theranostic Platform in Brain Tumor Treatment: Surmounting the Bench-to-Bedside Barriers.International journal of nanomedicine · 2026Review
- Metabolic reprogramming of glioma-associated macrophages identifies detoxification and energetic macrophages as drivers of immunosuppression and therapeutic vulnerability.Frontiers in immunology · 2026Article
- Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.Frontiers in immunology · 2026Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 5 institutions in 2 countries.
Mahmoud S AlghamriDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Kaushik BanerjeeDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Anzar A MujeebDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Ava MauserBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
Ayman TaherDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Rohit ThallaDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Brandon L McClellanDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Maria L VarelaDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Svetlana M StamatovicDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Gabriela Martinez-RevollarDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Anuska V AndjelkovicDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Jason V GregoryBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
Padma KadiyalaDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Alexandra CalinescuDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Jennifer A JiménezDepartment of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, United States.
April A ApfelbaumSeattle Children's Research Institute, University of Washington Seattle, Seattle, Washington 9810, United States.
Elizabeth R LawlorSeattle Children's Research Institute, University of Washington Seattle, Seattle, Washington 9810, United States.
Stephen CarneyDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Andrea CombaDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Syed Mohd FaisalDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Marcus BarissiDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Marta B EdwardsDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Henry AppelmanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Yilun SunDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio 44106, United States.ORCID 0000-0002-1341-382X
Jingyao GanDepartment of Pharmaceutical Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan 48109, United States.
Rose AckermannDepartment of Pharmaceutical Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan 48109, United States.
Anna SchwendemanBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
Marianela CandolfiInstituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, C1121 ABG Buenos Aires, Argentina.
Michael R OlinDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Joerg LahannBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-3334-2053
Pedro R LowensteinDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.
Maria G CastroDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States.ORCID 0000-0003-2237-2756
University of Michigan · USSeattle Children's Hospital · USCase Western Reserve University · USConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of Minnesota · US
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2MTraining Program in Tumor MicroenvironmentT32CA009676 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, Analisa Virginia DiFeo · 1992 to 2026
$7.3MOligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7MImmune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic StrategiesR37NS094804 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2021
$2.9MSystemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics (Supplement)R01NS124167 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, JOERG LAHANN · 2022 to 2026
$2.6MNovel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6MUncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.R01NS122165 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro · 2022 to 2026
$2.5MThe Role of Collagen and its Signaling Mechanisms in Glioma Progression and Invasion.R01NS122234 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Pedro R. Lowenstein · 2022 to 2026
$2.4MIdentifying intercellular circuits driving cell phenotypes within a nicheR01CA243916 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2019 to 2023
$2.3MNeuroimmunology of Malignant Brain Tumors: Innate MechanismsR01NS096756 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2016 to 2020
$2.1MInteractions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeuticsR01NS105556 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2018 to 2021
$1.9MMechanisms of glioma growth and invasion novel therapeutic strategiesR01NS082311 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2017
$1.7MNCI NIH HHS F31 CA247104NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA243916NCI NIH HHS T32 CA009676NIMHD NIH HHS L60 MD003100NINDS NIH HHS R01 NS076991NINDS NIH HHS R01 NS082311NINDS NIH HHS R01 NS096756NINDS NIH HHS R01 NS105556NINDS NIH HHS R01 NS122165NINDS NIH HHS R01 NS122234NINDS NIH HHS R01 NS122536NINDS NIH HHS R01 NS124167NINDS NIH HHS R21 NS123879NINDS NIH HHS R37 NS094804
Abstract
Glioblastoma (GBM) is an aggressive primary brain cancer, with a 5 year survival of ∼5%. Challenges that hamper GBM therapeutic efficacy include (i) tumor heterogeneity, (ii) treatment resistance, (iii) immunosuppressive tumor microenvironment (TME), and (iv) the blood-brain barrier (BBB). The C-X-C motif chemokine ligand-12/C-X-C motif chemokine receptor-4 (CXCL12/CXCR4) signaling pathway is activated in GBM and is associated with tumor progression. Although the CXCR4 antagonist (AMD3100) has been proposed as an attractive anti-GBM therapeutic target, it has poor pharmacokinetic properties, and unfavorable bioavailability has hampered its clinical implementation. Thus, we developed synthetic protein nanoparticles (SPNPs) coated with the transcytotic peptide iRGD (AMD3100-SPNPs) to target the CXCL2/CXCR4 pathway in GBM via systemic delivery. We showed that AMD3100-SPNPs block CXCL12/CXCR4 signaling in three mouse and human GBM cell cultures in vitro and in a GBM mouse model in vivo. This results in (i) inhibition of GBM proliferation, (ii) reduced infiltration of CXCR4
Indexed as
GlioblastomaGliomaImmunotherapyNanoparticlesAnimalsBenzylaminesCell Line, TumorCell ProliferationChemokine CXCL12CyclamsHumansMiceReceptors, CXCR4Signal TransductionTumor MicroenvironmentBenzylaminesChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanCyclamsplerixaforReceptors, CXCR4CXCL12/CXCR4gliomaimmunogenic cell deathimmunotherapynanoparticlessynthetic proteinsystemic deliverytumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.